Subject(s)
Lichen Nitidus , Humans , Child , Lichen Nitidus/diagnosis , Remission, Spontaneous , Follow-Up Studies , JapanSubject(s)
Lymphoma, Large-Cell, Anaplastic , Lymphoma, Primary Cutaneous Anaplastic Large Cell , Lymphoproliferative Disorders , Skin Diseases , Skin Neoplasms , Humans , Methotrexate/adverse effects , Lymphoma, Primary Cutaneous Anaplastic Large Cell/chemically induced , Lymphoma, Primary Cutaneous Anaplastic Large Cell/diagnosis , Lymphoma, Primary Cutaneous Anaplastic Large Cell/drug therapy , Skin Neoplasms/chemically induced , Skin Neoplasms/diagnosis , Skin Neoplasms/drug therapy , Lymphoma, Large-Cell, Anaplastic/chemically induced , Lymphoma, Large-Cell, Anaplastic/diagnosis , Lymphoma, Large-Cell, Anaplastic/drug therapy , Lymphoproliferative Disorders/chemically induced , Lymphoproliferative Disorders/diagnosis , Lymphoproliferative Disorders/pathologySubject(s)
Mycosis Fungoides , Skin Abnormalities , Skin Neoplasms , Humans , Mycosis Fungoides/diagnosis , Prognosis , Skin Neoplasms/diagnosisSubject(s)
Antifungal Agents/adverse effects , Carcinoma, Merkel Cell/etiology , Skin Neoplasms/etiology , Sunlight/adverse effects , Voriconazole/adverse effects , Biopsy , Carcinoma, Merkel Cell/diagnosis , Carcinoma, Merkel Cell/pathology , Churg-Strauss Syndrome/complications , Churg-Strauss Syndrome/drug therapy , Glucocorticoids/therapeutic use , Humans , Male , Merkel cell polyomavirus/genetics , Merkel cell polyomavirus/isolation & purification , Middle Aged , Pulmonary Aspergillosis/complications , Pulmonary Aspergillosis/drug therapy , Skin/drug effects , Skin/pathology , Skin/radiation effects , Skin Neoplasms/diagnosis , Skin Neoplasms/pathology , Time FactorsSubject(s)
Antineoplastic Agents, Immunological/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brain Neoplasms/therapy , Melanoma/therapy , Nivolumab/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Radiosurgery , Skin Neoplasms/therapy , Aged , Brain Neoplasms/enzymology , Brain Neoplasms/immunology , Brain Neoplasms/secondary , Chemotherapy, Adjuvant , Drug Resistance, Neoplasm , Female , Humans , MAP Kinase Kinase Kinases/antagonists & inhibitors , MAP Kinase Kinase Kinases/metabolism , Melanoma/enzymology , Melanoma/immunology , Melanoma/secondary , Mutation , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins B-raf/metabolism , Skin Neoplasms/enzymology , Skin Neoplasms/immunology , Skin Neoplasms/pathology , Treatment OutcomeSubject(s)
Hypotrichosis/congenital , Transcription Factors/genetics , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Hypotrichosis/diagnosis , Hypotrichosis/genetics , Japan , Male , Mutation, MissenseSubject(s)
Chronic Pain/drug therapy , Hypohidrosis/complications , Pain, Intractable/drug therapy , Risperidone/therapeutic use , Serotonin Antagonists/therapeutic use , Biopsy , Chronic Pain/etiology , Humans , Hypohidrosis/pathology , Male , Middle Aged , Pain, Intractable/etiology , Skin/pathology , Treatment OutcomeABSTRACT
KPU-105 (4), a potent anti-microtubule agent that contains a benzophenone was derived from the diketopiperazine-type vascular disrupting agent (VDA) plinabulin 3, which displays colchicine-like tubulin depolymerization activity. To develop derivatives with more potent anti-microtubule and cytotoxic activities, we further modified the benzophenone moiety of 4. Accordingly, we obtained a 4-fluorobenzophenone derivative 16j that inhibited tumor cell growth in vitro with a subnanomolar IC(50) value against HT-29 cells (IC(50)=0.5 nM). Next, the effect of 16j on mitotic spindles was evaluated in HeLa cells. Treatment with 3nM of 16j partially disrupted the interphase microtubule network. By contrast, treatment with the same concentration of CA-4 barely affected the microtubule network, indicating that 16j exhibited more potent anti-mitotic effects than did CA-4.